**UNITED STATES**
**SECURITIES AND EXCHANGE COMMISSION**
**WASHINGTON, DC 20549**

---

**FORM 8-K**

**CURRENT REPORT**
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report: April 23, 2026
(Date of earliest event reported)

BIORESTORATIVE THERAPIES, INC.
(Exact Name of Registrant as Specified in Charter)

| Nevada | 001-37603 | 30-1341024 |
|---|---|---|
| (State or Other Jurisdiction of Incorporation) | (Commission File No.) | (IRS Employer Identification Number) |

| 40 Marcus Drive, Melville, New York | 11747 |
|---|---|
| (Address of Principal Executive Offices) | (Zip Code) |

Registrant's telephone number, including area code: (631) 760-8100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

___ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

___ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

___ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

___ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, $0.0001 par value | BRTX | Nasdaq Capital Market |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ____

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ___

**Item 7.01 Regulation FD Disclosure**.

On April 23, 2026, BioRestorative Therapies, Inc. (the "Company") made available an updated corporate presentation (the "Presentation") that may be used by the Company in connection with presentations at conferences and investor meetings. The Presentation can be found on the Company's website, www.biorestorative.com. The Presentation is furnished as Exhibit 99.1 hereto.

The information in the Presentation is being furnished, not filed, pursuant to this Item 7.01. Accordingly, the information in the Presentation will not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing. The furnishing of the information in this Current Report on Form 8-K with respect to the Presentation is not intended to, and does not, constitute a determination or admission by the Company that the information in this Current Report on Form 8-K with respect to the Presentation is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.

**Item 9.01 Financial Statements and Exhibits**.

(d) Exhibits.

| Number | Description |
|---|---|
| 99.1 | Presentation Materials |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 23, 2026

**BIORESTORATIVE THERAPIES, INC.**

By: /s/ Robert Kristal
Robert Kristal
Chief Financial Officer

biorestorative therapies

# Regenerative Biology for Healthier Lives

## Corporate Presentation

April 2026

NASDAQ: BRTX



# Forward-Looking Statements

Statements in this presentation, including the information set forth as to the future financial or operating performance of BioRest are not current or historical factual statements may constitute "forward-looking" information within the meaning of the U.S. fed this presentation, such statements may include, among other terms, such words as "may," "will," "expect," "believe," "plan," "antici and other similar terminology. These statements reflect current expectations, estimates and projections regarding future events as to the date of this presentation. Readers should not place undue importance on forward-looking statements and should no date.

Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our a business plan or industry results, to differ materially from our expectations of future results, performance or achievements exp statements. These forward looking statements may not be realized due to a variety of factors, including without limitation: (i) ou revenues, and substantial losses since inception;(ii) our ability to obtain sufficient financing to initiate and complete our clinical t to timely and successfully develop and commercialize BRTX-100, our lead product candidate for the treatment of chronic lu patients in our clinical trials; (v) disruption to our access to the media (including cell culture media) and reagents the Compan cell therapy product candidates; (vi) failure of our clinical trials to demonstrate adequately the safety and efficacy of manufacturing capabilities to produce our product candidates at commercial scale quantities and lack of an alternative manu license rights with regard to our disc/spine technology; (ix) safety problems encountered by us or others developing new stem concerns surrounding the use of stem cell therapy which negatively impact the public perception of our stem cell products ar the development and marketing of cell therapies; (xii) our reliance on novel technologies that are inherently expensive and risky litigation to which the company may be subject, including potential exposure from the use of our product candidates in h reimbursement for our products and services from private and governmental insurers; (xv) our inability to protect our propriet federal, state, local, and international requirements; and (xvii) our current failure to meet the continued listing requirements common stock. See also "Risk Factors" set forth in the Company's most recent annual report filed with the SEC.

Many of these issues can affect the Company's actual results and could cause the actual results to differ materially from those statements made by, or on behalf of, the Company. You are cautioned that forward-looking statements are not guarantees place reliance on them. In formulating the forward-looking statements contained in this presentation, it has been assume affecting the Company and the economy generally will continue substantially in the ordinary course. These assumptions, alth preparation, may prove to be incorrect.

The description of the Company and its business in this presentation does not purport to be complete and is subject to the mo its business in the Company's annual, quarterly and current reports filed with the SEC.

# About BioRestorative

Clinical-stage regenerative medicine company developing advar
therapies using adult stem cell and tissue protocols for spine diso
disease, and regenerative aesthetics.

## Disc/Spine Late-Stage Clinical Program

BRTX-100, late-stage Phase 2 development of autologous bone marrow–
mesenchymal stem cell therapy for chronic lumbar disc disease designe
damaged intervertebral discs.

## BioCosmeceuticals (Commercial Platform):

Commercial biocosmeceutical skincare platform for skin health and long
marketing proprietary secretome-derived cosmetic and dermatologic pr
growth factors, cytokines) for professional aesthetics, medical-grade skir
use.

## Metabolic Preclinical Program (ThermoStem®):

Preclinical brown adipose-derived stem cell platform targeting obesity, T
metabolic disorders, leveraging metabolically active brown adipose tissu
regulate metabolic homeostasis and energy expenditure.

# Investment Highlights

## Late-Stage Clinical Asset with Regulatory Momentum

- BRTX-100 (late Phase 2 full enrolled) for chronic lumbar disc disease
- FDA Fast Track designation
- Spring 2027 topline clinical data expected

## Near-Term Commercialization of Regenerative Biologics Platform

- BioCosmeceuticals secretome-based regenerative skincare products
- Distribution through clinics, medspas, and aesthetic channels

## Large Addressable Markets with Significant Unmet Needs

- 64.5M U.S. adults suffer from chronic lower back pain
- $35B+ global medical aesthetics market

## Multiple Value Creation Catalysts

- Spring 2027 Phase 2 data readout
- Regulatory milestones and early Phase 3 development potential
- BioCosmeceuticals commercialization expansion and partnership opportunities

## Integrated Regenerative Medicine Platform

- cGMP ISO-7 biologics manufacturing facility
- Proprietary cell processing and therapeutic technologies

PRECLINICAL

MID-STAGE CLINICAL

## ThermoStem

**Source:**
Brown adipose-derived stem cells

**Application:**
Obesity, Type 2 diabetes, metabolic disorders

## BRTX-100

**Source:**
Bone marrow-derived mesenchymal stem cells

**Application:**
Chronic lumbar disease

# Robust Preclinical & Clinical Pipeline






* Polycystic ovarian syndrome

# Chronic Lumbar Disc Disease (cLDD)

| | |
|---|---|
| **258 M** | U.S. adult population |
| **64.5 M** | American adults with chronic lower back pain prevalence |
| **32 M** | American adults with diagnosed and treated disc degeneration |
| **15 M** | Americans suffering pain caused by a protruding or injured disc |
| **2.5 M** | Invasive Surgical Procedures per year; **$40 billion** in surgeries |



* Trinity Partners Report, "Degenerative Disc Disease US Market Assessment (Phase I)," Feb. 2016, Slide 9 of report.

# The Problem: Clinical & Economic



# Our Solution: BTRX-100



# BRTX-100: Technical Overview - Logistical /Clinical Process



# BRTX-100 in cLDD: Phase 2 Trial Design

## FDA Cleared IND 17275:

Phase 2 Randomized, Controlled Study Design in Patients with cLDD

### Design

- Study includes 105 subjects (2:1 product to placebo)
- 40,000,000 cells/dose
- Included subjects will have only one symptomatic diseased disc

### Primary Efficacy Endpoint

12 m, F/U at 24 m

**Improvement in function:** at least 30% increase in function based on Oswestry Disability Index questionnaires (ODI)

**Reduction of pain:** at least 30% decrease in pain as measured using a Visual Analogue Scale (VAS)

### Pati

- Sub
  dia
  pai
  sin
  his
  or
- Sub
  pre
  op

# Compelling Preliminary Phase 2 Clinical Data (36 Subjects): Meaningful Signals




**Presented at ISSCR 20**

FDA is requiring at least c
improvement in function
30% reduction in pain (V/
the clinical trial will be all
ultimately gain Biologics

**% Subjects ≥50**



# New Phase 2 ORS 2026 Blinded Data: Sustained Efficacy Acro

Percentage of patients achieving >50% improvement over time.












# The Convergence Standard: Simultaneous Pain and Functior



# BRTX-100: Key Differentiating Factors

| | SOURCE | CULTURING | CARR |
|---|---|---|---|
| biorestorative therapies | **Autologous** uses patient's own stem cells - 40 million | **Hypoxic cultured** in low oxygen environment (5%) | **Autologous** Lysate Co Adjuv |
| mesoblast | **Allogeneic** uses human derived stem cells (not from patient) - 6 million | **Normoxic cultured** with normal oxygen environment (~20%) | **Hyaluron Carri** |

## BRTX-100 Advantages

- Autologous cells means low to no risk of rejection, greater safety profile (introc potentially streamlined regulatory path
- Hypoxic culturing creates increased cell proliferation, greater plasticity, increa increased cell survival after application
- Autologous platelet lysate provides growth factors that interact with the cells,
- Low to no risk of safety concerns related to immunological and zoonotic (anim
- Strong runway for value creation with successful clinical results


PRECLINICAL
MID-STAGE CLINICAL
ThermoStem
Source:
Brown adipose-derived stem cells
Application:
Obesity, Type 2 diabetes, metabolic disorders
BRTX-100
Source:
Bone marrow-derived mesenchymal stem cells
Application:
Chronic lumbar disease
Bio
So
(n
fa
bi
te
ap
Ap
bo
re
ap

# BioRestorative's Cell-based Therapeutics And Biocosmece

**BioX-HR**
Delivers regenerative biosignals that assist healthy hair growth cycles

**BioX-HC**
Daily serum that delivers potent extracellular vesicles, rich in growth factors, peptides, and antioxidants to support optimal scalp function



**BioX-SC**
Daily bioactive exosome complex for skin vitality

**Ce**

**BioX-1**
Optimize
benefits
accessib

**BioX-3**
Formulat
concerns

**BioX-5**
Premiun
maximu

We are **pioneers** in the science of regenerative **cell-based** therapeutics and bio
advanced **biotechnology** with skincare innovation.

As a leading manufacturer of exosome-based formulations, we are redefining **s**
health through the power of regenerative science.

## The Skincare Market Is Being Disrupt

Three macro forces are colliding:




Exosomes, stem cell signaling, PRP, and biologics are now standard in aesthetics.

"Clean" and "natural" have been replaced by clinical validation and data.

## This creates a once-per-generation platfo

# How We Are Different

## Lineage Verification

Ensures every step, from donor umbilical cord MSC sourcing and culture conditions to isolation, purification, and final formulation is documented, verified, and auditable.

## BioEfficacy

High bioactivity for maximum results with scientifically measured efficacy in every formulation.

Manufac
Sys
quality st
trac
exceed t

# Advancing into High-Growth Regenerative Aesthetics Markets

## The Market

- Global Cosmetic market $6
- Global Regenerative market
- Regenerative products are t
- Market filled with products l and biological performance
- Bundle with existing proced indefinitely as the patient's

## Manufacturing

- cGMP ISO 7 Certified Facility
- Cellular Biology Engineering
- Multi-use facility highlights

## Products

- Cell-based biologics engine targeted for both clinical an

# BRTX-C: Going Commercial

## Our Approach

**Aesthetic Distributors**

**Regenerative Distributors**

**Direct Consun**

## Early Progress

Identified multiple high-quality opportunities and are in advanc

Global skincare manufacturer | High profile celebrit
Beauty supplier expanding markets | Large national r
Large national medspa franchise | Aesthetics & Regenerative Di

## PRECLINICAL

## MID-STAGE CLINICAL

### ThermoStem

**Source:**
Brown adipose-derived stem cells

**Application:**
Obesity, Type 2 diabetes, metabolic disorders

### BRTX-100

**Source:** Bone marrow-derived mesenchymal stem cells

**Application:** Chronic lumbar disease

# ThermoStem Program: Allogeneic Cell-based Therapy

**Target Conditions:** Obesity, Type 2 diabetes, and Metabolic disorders

**Cell Type:** Brown Fat

- Has been shown to regulate metabolic homeostasis in the body

**Components of Library:**

- Human Brown Adipose Tissue (BAT)
- White Adipose Tissue (WAT)
- Brown Adipose-derived Stem Cells (BADSC)

**Initial Proof of Concept:**

✓ Completed in small animal model

**Patent Portfolio:** Related BAT patent portfolio, including issued patents in the U.S., Australia and Japan

**Platform Program:**

For the development of c

# Metabolic Program Highlights


- First human stem cell derived BA
- Creation of first human 3D engine adipose tissue construct (aBAT)
- Successful delivery of 3D aBAT co
- Transplantation of aBAT lowered
- Transplantation of aBAT decreas
- Published initial proof of concept

# Metabolic Program Clinical Pathway

## File DMF with FDA

Expect filing a Drug Master File ("DMF") with the FDA to facilitate licensing opportunities around ThermoStem.

## Pre-IND Meeting with FDA

Scheduling Pre-IND meeting with FDA to discuss first-in-man fast-track regulatory pathways.

# Our Opportunities are Well-Protected

| PROGRAM | INDICATION | PATENT TITLES |
|---|---|---|
| brt discx | Disc / Spine | • Methods and Compositions to facilitate repair of avascular tissue<br>• Surgical Methods and Compositions to facilitate repair of avascular tissue<br>• Therapeutic Delivery Device |
| ThermoStem | Metabolic | • Brown Fat Compositions and Methods<br>• Human Brown Adipose Derived Stem Cells and Uses<br>• Non-naturally occurring three-dimensional (3D) Brown Adipose-Derived Stem Cell aggregates and methods of generating and using the same |

# Near Term Catalysts

| PROGRAM | 2026 | | | | 2027 & BEYOND |
|---|---|---|---|---|---|
| | Q1 | Q2 | Q3 | Q4 | |
| **BRTX-100 Phase 2** | | | | | |
| Enrollment Complete | | | | | **2027 (Q2) -** 1-Yea |
| Clinical data presented at ORS 2026 | | | | | **2028 (Q2) -** 1-Yea |
| Clinical data presented at ISCT 2026 | | | | | |
| Publish blinded BRTX-100 clinical data | | | | | |
| File IND for allogeneic (off-the-shelf) BRTX-100 | | | | | |
| **BRTX-100 Phase 3** | | | | | |
| Submit RMAT application | | | | | **2027 (Q4) -** Enroll |
| Potency assay complete (supports BLA requirements) | | | | | **2028 (Q4) -** 1-Yea |
| Phase 3 IND clearance | | | | | **2029 (Q4) -** 1-Yea |
| Enrollment Begins | | | | | |
| First Phase 3 patient dosed | | | | | |
| **BioCosmeceutical** | | | | | |
| Complete small-animal wound healing study (IND-enabling) | | | | | |
| Publish BRTX-Cosmetic manuscript | | | | | |
| Advance commercialization milestones | | | | | |
| **ThermoStem** | | | | | |
| Biodistribution/Toxicology Animal Study | | | | | |



2026 Catalysts

# Recent Accomplishments

- ✓ Announced FDA clearance of important BRTX-100 clinical study protocol amendment (replaces saline injection with sham injection in control arm)
- ✓ Completed enrollments in Phase 2 BRTX-100 clinical trial
- ✓ Reported positive preliminary Phase 2 BRTX-100 study data (36 patient) in cLDD
- ✓ Received FDA Fast Track Designation for BRTX-100 in cLDD
- ✓ FDA cleared IND for Phase 2 BRTX-100 trial in cCDP
- ✓ Developed novel exosome-based biologic for obesity
- ✓ Expanded ThermoStem patents in U.S., Europe, Israel, and Japan
- ✓ Initiated discussions with an undisclosed commercial stage regenerative medicine company on potential ThermoStem IP licensing
- ✓ Announced commercial biocosmeceutical agreement with Cartessa
- ✓ Received expanded tissue license from New York State Dept. of Health

# Key Metrics

| CURRENT CAPITALIZATION | S |
|---|---|
| Common Shares Outstanding | 25.5 |
| Cash | $ 7.9 |
| Debt | |
| Warrants Outstanding | 19,780 |

* As of 03/26/2026
** As of 12/31/2025 year end, add $5.0 million gross proceeds from Rodman deal of Feb 2026

# Experienced Leadership

## Lance Alstodt
**Chairman & CEO**

- 30+ years leading, advising and operating companies within the Healthcare sector
- Founder, MedVest Capital, (a Healthcare investment fund created in 2013)
- Former head of Medical Technology investment banking group at JP Morgan, BAML and Leerink Partners

## Robert Kristal
**Chief Financial Officer**

- 25+ years on Bay Street and Wall Street
- Most recently served as Director of Research (DOR) at a healthcare-focused investment bank
- Career has spanned Trading, Sales, Investment Banking and Research

## Francisco Silva
**Vice President of R&D**

- 20+ years in the R&D of cell-based and off-the-shelf therapeutics
- Established BRTX's high-throughput stem cell research program leveraging academic and industrial experience
- Inventor on multiple cell therapy patents; author of manuscripts in translational stem cell research
- Section Editor of the newly launched Regenerative Medicine section of the peer-reviewed *Journal of Translational Medicine*

## Cryst
**Head of G**

- 20 yea
- Recent Comm
- Comm
- Holds r

## Suran
**Director o**

- 15 year and tis
- Severa
- Bristol

## Micha
**Director o**

- Tissue
- 10+ yea

## Zack L
**Director,**

- 20+ ye
- Leader Medici

# In Conclusion

- cGMP ISO-7 Certified Clean room
- Disruptive Platform Technologies in Cellular Therapy
- Strong Preliminary Data Indicative of Positive Trial Outcomes
- Active Phase 2 Trial in Spine
- Addressing Mult with Unmet Nee
- Opportunity for I Partnerships in C
- Strong Intellectu
- Experienced Ma Scientific Adviso

biorestorative
therapies

40 Marcus Drive, Suite 1
Melville, NY 11747
(631) 760-8100
biorestorative.com

# Appendix

# BRTX-100: Positive Human Data

**Human data from studies of therapies similar to BRTX-100 show reduced p**
**and an absence of significant safety issues with a durable r**

Centeno et al. J Transl Med (2017) 15:197
DOI 10.1186/s12967-017-1300-y

Journal of Translational Medicine

RESEARCH Open Access

Treatment of lumbar degenerative disc disease-associated radicular pain with culture-expanded autologous mesenchymal stem cells: a pilot study on safety and efficacy

Christopher Centeno[1,2], Jason Markle[1], Ehren Dodson[2*], Ian Stemper[2], Christopher J. Williams[1], Matthew Hyzy[1], Thomas Ichim[3] and Michael Freeman[4]

Original Clinical Science—General

**Intervertebral Disc Repair by Mesenchymal Bone Marrow ( Controlled Trial**

David C. Noriega, MD, PhD,[1] Francisco Ardura, MD, PhD,[1] Rubé Miguel Ángel Martín-Ferrero, MD, PhD,[1] Israel Sánchez-Lite, MD, Mercedes Alberca, PhD,[3] Verónica García, PhD,[3] José M. Morale Ana Sánchez, MD, PhD,[5] and Javier García-Sancho, MD, PhD[5]



Kumar et al. Stem Cell Research & Therapy (2017) 8:262
DOI 10.1186/s13287-017-0710-3

Stem Cell Research & Therapy

RESEARCH Open Access

Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study

Hemant Kumar[†1], Doo-Hoe Ha[†2], Eun-Jong Lee[3†], Jun Hee Park[4], Jeong Hyun Shim[4], Tae-Keun Ahn[5], Kyoung-Tae Kim[6], Alexander E. Ropper[7], Seil Sohn[1], Chung-Hun Kim[8], Devang Kashyap Thakor[9], Soo-Hong Lee[10*] and In-Bo Han[1*]

Stem Cells and Development > Vol. 28, No. 17 > Original Research

**The Traceability of Mesenchy After Injection Into Degenera with Low Back Pain**

Helena Barreto Henriksson, Nikolaos Papadimitriou, Daphne Hingert, Adad

**Published Online:** 23 Aug 2019 | https://doi.org/10.1089/scd.2019.0074

# BRTX-100: Cleared DSMB June 2023

- Unanimous approval by the DSMB to continue trial without changes
- BRTX-100 is safe and well tolerated
- All 4 subjects successfully dosed with either 40 mil hMSCs or placebo
- First time 40 million cells injected in a human subject
- 3:1 randomization
- No Significant Adv
- VAS, ODI, SF-12, RM measure pain and
- Opportunity to lev clinical package

# BRTX-100: Clinical Snapshot

Lead investigational therapeutic product

Autologous (patient's own) cell-based biologic

Hypoxic (low oxygen) cultured, bone marrow-derived

Prior human data provides insight into the potential safety and efficacy of BRTX-100

Ongoing FDA authorized Phase 2 clinical trial



1) Trinity Partners Report, "Degenerative Disc Disease US Market Assessment (Phase I)," Feb. 2016, Slide 9 of report.

# Scientific Advisory Board

## Wayne Marasco, MD, PDt
**Chairman of SAB**

- Principal Faculty Member of Harvard Stem Cell Institute
- Professor in the Department of Cancer Immunology & AIDS at the Dana-Farber Cancer Institute
- Professor of Medicine at Harvard Medical School

## Jason Lipetz, MD
**Chairman of SAB Sub Committee**
**Disc Advisory Board**

- Chief of Spine Medicine for the Northwell Health Spine Center
- Founder of Long Island Spine Rehabilitation Medicine

## Wayne Olan, MD Clinical
**Director of Regenerative Disc / Spine Program**

- Board-certified Interventional Neuroradiologist
- Director of Endovascular and Minimally Invasive Neurosurgery at the George Washington University Medical Center

## Christopher Plastaras, MD
**Member Disc Advisory Board**

- MossRehabs' Clinical Director of Musculoskeletal Spine & Sports Rehabilitation Medicine